PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
Metrics: PDF 504 views | HTML 453 views | ?
Simona Ultimo1,*, Carolina Simioni1,*, Alberto M. Martelli2, Giorgio Zauli1, Camilla Evangelisti3, Claudio Celeghini4, James A. McCubrey5, Giorgia Marisi6, Paola Ulivi6, Silvano Capitani1,7, Luca M. Neri1
1Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
2Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
3Institute of Molecular Genetics, Rizzoli Orthopedic Institute, National Research Council, Bologna, Italy
4Department of Life Sciences, University of Trieste, Trieste, Italy
5Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA
6Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy
7LTTA Center, University of Ferrara, Ferrara, Italy
*These authors contributed equally to this work
Luca M. Neri, email: firstname.lastname@example.org
Silvano Capitani, email: email@example.com
Keywords: PI3K isoforms, Bcr-Abl, Ph+ B-acute lymphoblastic leukemia, autophagy, tyrosine kinase inhibitors
Received: December 08, 2016 Accepted: February 12, 2017 Published: February 20, 2017
B-acute lymphoblastic leukemia (B-ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. Philadelphia chromosome-positive (Ph+) B-ALL is a subtype that expresses the Bcr-Abl fusion protein which represents a negative prognostic factor. Constitutive activation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) network is a common feature of B-ALL, influencing cell growth and survival. In the present study, we aimed to investigate the efficacy of PI3K isoform inhibition in B-ALL cell lines harboring the Bcr-Abl fusion protein.
We studied the effects of anti Bcr-Abl drugs Imatinib, Nilotinib and GZD824 associated with PI3K isoform inhibitors. We used a panel of six compounds which specifically target PI3K isoforms including the pan-PI3K inhibitor ZSTK474, p110α BYL719 inhibitor and the dual p110γ/p110δ inhibitor IPI145. The effects of single drugs and of several drug combinations were analyzed to assess cytotoxicity by MTS assays, apoptosis and autophagy by flow cytometry and Western blot, as well as the phosphorylation status of the pathway.
ZSTK474, BYL719 and IPI145 administered in combination with imatinib, nilotinib and GZD824 for 48 h, decreased cell viability, induced apoptosis and autophagy in a marked synergistic manner.
These findings suggest that selected PI3K isoform inhibitors used in combination with anti Bcr-Abl drugs may be an attractive novel therapeutic intervention in Ph+ B-ALL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.